New drug application received by FDA for levoketoconazole for the treatment of endogenous Cushing’s syndrome

The submission for this 2S,4R enantiomer of ketoconazole is supported by data from the phase 3 SOMICS and LOGICS studies which demonstrated a statistically significant normalisation rate of urinary free cortisol at six months vs placebo.

Biospace Inc.